Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02661022 · OUTCOME

Number of Patients With Dose-limiting Toxicities and Treatment-emergent Adverse Events

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma · Source last updated 2024-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
For a 28-day cycle, Cycle 1

What was measured

To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma

Groups in this outcome

SL-401 7 µg/kg/Day

SL-401 7 µg/kg/day in combination with pomalidomide and dexamethasone

SL-401 9 µg/kg/Day

SL-401 9 µg/kg/day in combination with pomalidomide and dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
SL-401 7 µg/kg/Day7
SL-401 9 µg/kg/Day2

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
SL-401 7 µg/kg/Day7Not reportedNot reportedNot reportedNot reported
SL-401 9 µg/kg/Day2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    2. group Id
      OG001
      value
      2
    units
    Participants
description
To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma
groups
  1. description
    SL-401 7 µg/kg/day in combination with pomalidomide and dexamethasone
    id
    OG000
    title
    SL-401 7 µg/kg/Day
  2. description
    SL-401 9 µg/kg/day in combination with pomalidomide and dexamethasone
    id
    OG001
    title
    SL-401 9 µg/kg/Day
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
For a 28-day cycle, Cycle 1
title
Number of Patients With Dose-limiting Toxicities and Treatment-emergent Adverse Events
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice